PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has received affirmation by the Public Health Service of the U. S. Centers for Disease Control and Prevention (the “CDC”) and the Zentrale Kommission für die Biologische Sicherheit (the “ZKBS”), the Central Commission for Biological Safety in Germany, that Advaxis strains, constructs and immunotherapies (the “Advaxis Agents”) have been attenuated to the point that they are classified as non-pathogenic materials for handling and shipment. This is not the same as an assessment of safety for medical use by the FDA.
